Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics Inc (NQ: EWTX )

26.05 +0.18 (+0.72%)
Streaming Delayed Price Updated: 1:59 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 366,104
Open 26.17
Bid (Size) 26.04 (2)
Ask (Size) 26.09 (2)
Prev. Close 25.87
Today's Range 25.87 - 27.09
52wk Range 5.120 - 30.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? 
Via MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates

Performance

YTD
+136.86%
+136.86%
1 Month
+29.05%
+29.05%
3 Month
+49.06%
+49.06%
6 Month
+45.07%
+45.07%
1 Year
+326.43%
+326.43%

More News

Read More
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
Via Benzinga
Exposures Fossil Fuels
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Via MarketBeat
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
Via The Motley Fool
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
Via Benzinga
Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Via Investor's Business Daily
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
From Edgewise Therapeutics
Via Business Wire
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
7 Small-Cap Stocks to Buy for Large-Scale Gains
Via InvestorPlace
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
Via Investor's Business Daily
Topics Government
Exposures Political
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Via Investor's Business Daily
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
Via Investor's Business Daily
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
From Edgewise Therapeutics
Via Business Wire
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.